StemCells, Inc. Completes Enrollment of First Cohort in Phase II Pathway Study for Cervical Spinal Cord Injury

By: via Benzinga
StemCells, Inc. (Nasdaq: STEM), a leading stem cell company developing novel cell-based therapeutics for treating diseases of the ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.